Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › REIMAGINE 1 (early T2D)

REIMAGINE 1 (early T2D)

CagriSema · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
CagriSema
Population
t2d
Official title
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Sponsor
Novo Nordisk A/S
Phase
3
Registry status
completed · 2024-03 → 2025-10
Participants
189
Duration
40 weeks
Registry
NCT06323174

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
CagriSema 2.4/2.4 mgt2d40189−14.3 % vs −2.8 %
Δ −11.5 pp
−14.3 % vs −2.8 %
Δ −11.5 pp
———————verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (1)
  • CagriSema 2.4/2.4 mg · weight_eff · Results, MRI sub-study
    CagriSema reduced BW vs pbo (2.4 mg/2.4 mg: −14.3%; 1.0 mg/1.0 mg: −11.2%; pbo: −2.8%;

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: REIMAGINE 1 (early T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/reimagine-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.